US91307C1027 - Common Stock
UNITED THERAPEUTICS CORP
NASDAQ:UTHR (5/9/2024, 11:56:10 AM)
264.31
+3.22 (+1.23%)
United Therapeutics Corp. is a biotechnology company, which engages in the development and commercialization of products for patients with chronic and life-threatening conditions. The company is headquartered in Silver Spring, Maryland and currently employs 985 full-time employees. The firm markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Tyvaso (treprostinil) Inhalation Solution (Tyvaso), which includes the Tyvaso Inhalation System; Tyvaso DPI (treprostinil) Inhalation Powder (Tyvaso DPI); Remodulin (treprostinil) Injection (Remodulin); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca). Tyvaso and Tyvaso DPI are also approved to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company also markets and sells an oncology product, Unituxin (dinutuximab) Injection (Unituxin), which is approved for treatment of high-risk neuroblastoma, and the Remunity Pump for Remodulin (Remunity). Tyvaso DPI incorporates the dry powder formulation technology and Dreamboat inhalation device technology used in MannKinds Afrezza (insulin human) Inhalation Powder product.
UNITED THERAPEUTICS CORP
1000 Spring St
Silver Spring MARYLAND 20910
P: 13016089292
CEO: Martine A. Rothblatt
Employees: 985
Website: https://www.unither.com/
The biotech sector offers significant potential for growth. These 3 biotech stocks to double your money are noteworthy candidates.
UTHR stock results show that United Therapeutics beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.
Here you can normally see the latest stock twits on UTHR, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: